Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis
Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors. Development of distant metastasis is frequent, even in patients undergoing initial curative surgery. Trabectedin, a tetrahydroisoquinoline alkaloid isolated from the Caribbean marine tunicate Ecteinascidia turbinata, was a...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
13 October 2010
|
| In: |
Marine drugs
Year: 2010, Volume: 8, Issue: 10, Pages: 2647-2658 |
| ISSN: | 1660-3397 |
| DOI: | 10.3390/md8102647 |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.3390/md8102647 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1660-3397/8/10/2647 
|
| Author Notes: | Thomas Schmitt, Eva Keller, Sascha Dietrich, Patrick Wuchter, Anthony D. Ho and Gerlinde Egerer |
| Summary: | Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors. Development of distant metastasis is frequent, even in patients undergoing initial curative surgery. Trabectedin, a tetrahydroisoquinoline alkaloid isolated from the Caribbean marine tunicate Ecteinascidia turbinata, was approved in 2007 for patients with advanced STS after failure of anthracyclines and ifosfamide, or for patients unsuited to receive these agents. In this study, we retrospectively analyzed 25 patients who had been treated with trabectedin at our institution between 2007 and 2010. |
|---|---|
| Item Description: | Gesehen am 15.06.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1660-3397 |
| DOI: | 10.3390/md8102647 |